Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses.
about
DNA immunization as a technology platform for monoclonal antibody inductionEffect of vaccine administration modality on immunogenicity and efficacy.Impact of immunization technology and assay application on antibody performance--a systematic comparative evaluationInfluenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferretsEvaluation of neutralizing efficacy of monoclonal antibodies specific for 2009 pandemic H1N1 influenza A virus in vitro and in vivo.Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses.Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus.Polyvalent DNA vaccines expressing HA antigens of H5N1 influenza viruses with an optimized leader sequence elicit cross-protective antibody responses.Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch.Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles.Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles.New classes of orthopoxvirus vaccine candidates by functionally screening a synthetic library for protective antigens.Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.Prime-boost immunization using a DNA vaccine delivered by attenuated Salmonella enterica serovar typhimurium and a killed vaccine completely protects chickens from H5N1 highly pathogenic avian influenza virus.Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice.Mucosal vaccines against respiratory syncytial virusHeterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease.Technologies for enhanced efficacy of DNA vaccines.Pilot Study on the Use of DNA Priming Immunization to Enhance Y. pestis LcrV-Specific B Cell Responses Elicited by a Recombinant LcrV Protein Vaccine.Vector Design for Improved DNA Vaccine Efficacy, Safety and Production.Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formationDNA vaccination in the skin using microneedles improves protection against influenza.Active opioid use does not attenuate the humoral responses to inactivated influenza vaccine.Technical transformation of biodefense vaccines.Heterologous prime-boost vaccination.Cross reactivity of serum antibody responses elicited by DNA vaccines expressing HA antigens from H1N1 subtype influenza vaccines in the past 30 years.DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus.DNA immunization.The strategic use of novel smallpox vaccines in the post-eradication world.A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines.Programmed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8+ T cell immunity.Identification of Aim2 as a sensor for DNA vaccines.Potent monoclonal antibodies against Clostridium difficile toxin A elicited by DNA immunizationProduction and characterization of monoclonal antibodies against the hemagglutinin of H5N1 and antigenic investigation of avian influenza H5N1 viruses isolated from China.An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial.The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.Clostridium perfringens beta toxin DNA prime-protein boost elicits enhanced protective immune response in mice.A Review of DNA Vaccines Against InfluenzaNew approaches to vaccination
P2860
Q26751432-49AC0EF6-A730-4E2F-A971-FA319913F13DQ27692376-E00EF07C-199D-4472-A42D-78BA0AC80342Q28741074-982975C8-3E10-41F1-9F84-2BFEB4D59C26Q28742787-AAD54913-70D6-432D-BF89-3786A78C4842Q30353823-7E7930D9-DB1A-4975-B3DB-FD84C4B19E21Q30368929-77DFF8F0-A1C0-4C5C-AF1F-471319E19F01Q30399477-28A06ED8-9C91-4854-AFBC-1FDD0B29E3DBQ30411149-2954B560-1180-423F-8026-3B1284018CD8Q30415387-14A86986-FADF-472A-A3F7-509C28199D75Q30418340-AB52B818-2191-429E-A9EF-F8F96E7FFEE1Q30430152-111935AA-4308-4644-AC09-F9F1ECCB9DA9Q33508318-C2FE7971-6846-40A3-B5BD-4BD66D528FC7Q33759392-8256624A-9806-49C0-9972-2F73FF658CA3Q33768698-7EF2A261-0D3F-428D-99CB-AE007D098B8BQ33818084-29CD6122-0B78-43C6-B1F0-B3A8BC281A7EQ33837530-9A61D63E-C71A-40DC-BC32-ECD8CC5E0269Q34438489-EA9ADA6F-24FA-41B3-991E-D2633B679AD8Q35183183-E306C750-D62D-48BB-857B-761F6465500BQ35802958-1A183B51-78A0-4421-A8EA-AD95819413C2Q35826610-DE5FAB8F-38CE-4C6E-A5C7-1A4BEB3B2411Q35826665-10A7AB88-19A6-4A3B-8E56-0589F9204694Q35893538-4D20B050-46A3-42A9-89EB-9D4F919ED71CQ36085414-BFF51338-0CF3-49E7-BA36-BF4466D19FCEQ36659174-C7602D8F-AB3F-4903-8654-D6F3150737E4Q37058898-595D6435-CD29-45AB-B6AC-DBE2D455578BQ37509586-E81D06E8-BE1E-4787-99CB-1D0131BF69CBQ37530450-8555FCB1-A1EF-458F-B4D8-8BE613940216Q37530479-48D501CC-461E-4774-B12E-CEF0BD2A9B5DQ37576264-B507FA62-CFF2-4B79-A778-044B508A6940Q37909421-FB7547A0-F660-431C-A889-2F469CEDD1DFQ40294097-4294A359-6621-49BF-BE9B-EBEBF0712F3FQ41526077-2DD90228-A389-481E-BA1D-58DBF08510A1Q41609361-981092A5-7DB0-4C69-BF12-F31D9E7C5773Q41899304-540CDD7D-ECE2-44E4-BE5B-989FAA026430Q43173327-10A7DFC8-B443-4F46-8059-21D04E1FDC52Q47105782-9ECB6D30-21B6-4E36-8800-897898AB959FQ47244891-972C2771-1BCD-4673-94BF-EF77910AECAAQ50639945-D209CE9A-CE8D-4D5F-B8BC-9069727B8C96Q57094261-6C3939DC-D2C9-44AB-87AC-6464CA0297FEQ57170110-7C7EAB2A-60CA-4350-AAD6-ACABBAD1C83F
P2860
Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Heterologous HA DNA vaccine pr ...... H3 serotype influenza viruses.
@ast
Heterologous HA DNA vaccine pr ...... H3 serotype influenza viruses.
@en
type
label
Heterologous HA DNA vaccine pr ...... H3 serotype influenza viruses.
@ast
Heterologous HA DNA vaccine pr ...... H3 serotype influenza viruses.
@en
prefLabel
Heterologous HA DNA vaccine pr ...... H3 serotype influenza viruses.
@ast
Heterologous HA DNA vaccine pr ...... H3 serotype influenza viruses.
@en
P2093
P2860
P50
P1433
P1476
Heterologous HA DNA vaccine pr ...... H3 serotype influenza viruses.
@en
P2093
Chris Parker
Jessica Taaffe
Shixia Wang
P2860
P304
P356
10.1016/J.VACCINE.2008.04.073
P407
P577
2008-05-19T00:00:00Z